N/A
Manufactured by AbbVie Inc.
15,159 FDA adverse event reports analyzed
Last updated: 2026-04-14
GLECAPREVIR AND PIBRENTASVIR is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by AbbVie Inc.. The most commonly reported adverse reactions for GLECAPREVIR AND PIBRENTASVIR include FATIGUE, HEADACHE, NAUSEA, PRURITUS, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GLECAPREVIR AND PIBRENTASVIR.
Out of 10,811 classified reports for GLECAPREVIR AND PIBRENTASVIR:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 15,159 FDA FAERS reports that mention GLECAPREVIR AND PIBRENTASVIR. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FATIGUE, HEADACHE, NAUSEA, PRURITUS, DIARRHOEA, RASH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list AbbVie Inc. in connection with GLECAPREVIR AND PIBRENTASVIR. Always verify the specific product and NDC with your pharmacist.